Enhanced antibacterial effect of the novel T4-like bacteriophage KARL-1 in combination with antibiotics against multi-drug resistant Acinetobacter baumannii

Усиленный антибактериальный эффект нового Т4-подобного бактериофага KARL-1 в комбинации с антибиотиками против мультирезистентной Acinetobacter baumannii
Eva Miriam Buhl, Alex Krüttgen, Hans‐Peter Horz, Klaus Ritter, Adam Wahida, Mathias Jansen, Simone Latz, H. Häfner
2018-09-14

Acinetobacter baumanniiT4-like bacteriophage KARL-1meropenem and colistinmultidrug-resistant bacteriaphage-antibiotic combination therapy
Abstract The continuing rise of infections caused by multi-drug resistant bacteria has led to a renewed interest in bacteriophage therapy. Here we characterize phage vB_AbaM-KARL-1 with lytic activity against multi-drug resistant clinical isolates of Acinetobacter baumannii (AB). Besides genomic and phenotypic phage analysis, the objective of our study was to investigate the antibacterial outcome when the phage acts in concert with distinct antibiotics. KARL-1 belongs to the family of Myoviridae and is able to lyse 8 of 20 (40%) tested clinical isolates. Its double-stranded DNA genome consists of 166,560 bp encoding for 253 open reading frames. Genome wide comparison suggests that KARL-1 is a novel species within the subfamily Tevenvirinae , sharing 77% nucleotide identity (coverage 58%) with phage ZZ1. The antibacterial efficacy at various multiplicities of infection (MOI) was monitored either alone or in combination with meropenem, ciprofloxacin, and colistin. A complete clearance of liquid cultures was achieved with KARL-1 at an MOI of 10 −1 and meropenem (>128 mg/l). KARL-1 was still effective at an MOI of 10 −7 , but antibacterial activity was significantly augmented with meropenem. While ciprofloxacin did generally not support phage activity, the application of KARL-1 at an MOI of 10 −7 and therapeutic doses of colistin significantly elevated bacterial suppression. Hence, KARL-1 represents a novel candidate for use against multi-drug resistant AB and the therapeutic outcome may be positively influenced by the addition of traditional antibiotics.
1
Ciprofloxacin generally did not support KARL-1 activity, indicating that antibiotic-phage interactions were antibiotic-specific.
2
KARL-1 completely cleared liquid cultures at an MOI of 10−1 when combined with meropenem concentrations above 128 mg/l.
3
KARL-1 is a novel T4-like Myoviridae phage species with a 166,560-bp genome encoding 253 open reading frames.
4
KARL-1 remained active at an MOI of 10−7, with antibacterial suppression significantly enhanced by meropenem and therapeutic-dose colistin.
5
The phage lysed 8 of 20 (40%) tested multidrug-resistant Acinetobacter baumannii clinical isolates.

T4-like bacteriophage KARL-1 and multidrug-resistant clinical isolates of Acinetobacter baumannii

The antibacterial efficacy of KARL-1 alone and in combination with meropenem, ciprofloxacin, or colistin, including effects of multiplicity of infection and bacterial suppression

Publication Details
Publication Date
2018-09-14
Journal
Publisher
ISSN
Cited by
119
Access Type
Author Information
Authors
Eva Miriam Buhl
Alex Krüttgen
Hans‐Peter Horz
Klaus Ritter
Adam Wahida
Mathias Jansen
Simone Latz
H. Häfner
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%